Table 5.
Frequency distribution of more common adverse events and serious adverse events in persons with relapsing remitting multiple sclerosis treated with terifluonomide.
| Terifluonomide | 28 (12), No. (%) | |
|---|---|---|
| Adverse events | Arterial hypertension | 6 (2.6) |
| Transaminases elevation | 5 (2.1) | |
| Alopecia | 4 (1.7) | |
| Nausea, vomiting | 3 (1.3) | |
| Neuropathy | 2 (1.7) | |
| Lymphopenia | 2 (0.9) | |
| Epstein–Barr virus reactivation | 1 (0.4) | |
| Flushing | 1 (0.4) | |
| Articular pain | 1 (0.4) | |
| Serious adverse events | Cancers | 2 (0.9) |
| Severe vomiting | 1 (0.4) |